AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AngioDynamics (ANGO) PT Raised to $13 at Oppenheimer
July 16, 2024 3:27 PM EDTOppenheimer analyst Steven M. Lichtman raised the price target on AngioDynamics (NASDAQ: ANGO) to $13.00 (from $12.00) while maintaining a Outperform rating.
The analyst comments "ANGO's F4Q24 sales of $71.1M (+1.9% y/y pro forma) were in line with the key higher margin/growth... More
